US StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

Maison Solutions

0.8905

-0.0103-1.14%

Post-market: 0.90000.0096+1.07%19:58 EDT

Volume:17.98K

Turnover:16.04K

Market Cap:17.53M

PE:-12.13

High:0.9007

Open:0.9006

Low:0.8766

Close:0.9007

Loading ...

Overview Company News Filings

BRIEF-Maison Solutions announces closure Of Super HK of El Monte - SEC Filing

Maison Solutions Inc. Closes El Monte Supermarket

Maison Solutions Inc - Announces Closure of Closure of Super HK of El Monte - SEC Filing

THOMSON REUTERS

Press Release: Viasat Announces Comprehensive Agreement with Ligado Networks

Think Palantir Stock Is Too Expensive? 1.28 Billion Reasons That Might Change Your Mind

Marjorie Taylor Greene Just Loaded Up on This Monster Artificial Intelligence (AI) Stock That Continues to Crush the Market

Press Release: Agenus Reports Q1 2025 Financial Results and Key Business Updates

Bitcoin, Ethereum, XRP, Dogecoin Slide As Markets Brace For Fed Interest Rate Decision

Prediction: Palantir's New Deal With NATO Could Revolutionize How Artificial Intelligence (AI) Is Used in the Public Sector. Here's Why.

Adagene Announces Upcoming Poster Presentation on Masked Anti-CTLA-4 SAFEbody® ADG126 (Muzastotug) at American Society of Clinical Oncology (ASCO) Annual Meeting

Leap Therapeutics to Host Virtual KOL Event to Discuss Sirexatamab (DKN-01) in Second-line Patients with Advanced Microsatellite Stable Colorectal Cancer

BRIEF-Maison Solutions Files Prospectus For Proposed Resale From Time To Time By Selling Stockholder Of Up To 62.7 Million Shares Of Class A Common Stock

Maison Solutions Inc. (NASDAQ:MSS) Might Not Be As Mispriced As It Looks After Plunging 25%

Simply Wall St.

Adagene to Present at Stifel’s 2025 Virtual Targeted Oncology Forum

Sensei Biotherapeutics Reports Favorable Preliminary Dose Expansion Data for Solnerstotug in PD-(L)1 Resistant Tumors

Penny Stock Leap Therapeutics Unveils Positive Data From Experimental Combo Therapy For Colorectal Cancer

Leap Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results

Leap Therapeutics Reports Positive Updated Data from Sirexatamab Colorectal Cancer Study

Adagene Reports Full Year 2024 Financial Results and Provides Corporate Update

Maison Solutions Names Xintong Ma as Chief Strategy Officer

MT Newswires Live

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/stock/MSS/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"MSS","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"MSS\",,,,,undefined,":{"symbol":"MSS","market":"US","secType":"STK","nameCN":"Maison Solutions","latestPrice":0.89045,"timestamp":1750449600000,"preClose":0.900728,"halted":0,"volume":17979,"hourTrading":{"tag":"盘后","latestPrice":0.9,"preClose":0.89045,"latestTime":"19:58 EDT","volume":2481,"amount":2240.1836,"timestamp":1750463939286},"delay":0,"floatShares":6157619,"shares":19690476,"eps":-0.073391,"marketStatus":"Market Closed","change":-0.010278,"latestTime":"06-20 16:00:00 EDT","open":0.9006,"high":0.9007,"low":0.8766,"amount":16038.3035904,"amplitude":0.026756,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-0.073391,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1750665600000},"marketStatusCode":7,"adr":0,"listingDate":1686801600000,"exchange":"NASDAQ","adjPreClose":0.900728,"preHourTrading":{"tag":"盘前","latestPrice":0.9007,"preClose":0.9007,"latestTime":"08:02 EDT","volume":730,"amount":657.511,"timestamp":1750420938145},"postHourTrading":{"tag":"盘后","latestPrice":0.9,"preClose":0.89045,"latestTime":"19:58 EDT","volume":2481,"amount":2240.1836,"timestamp":1750463939286},"volumeRatio":0.1939628666464606},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"MSS\",,,,,undefined,":{"symbol":"MSS","floatShares":6157619,"roa":"0.97%","roe":"-12.63%","lyrEps":-0.186459,"volumeRatio":0.1939628666464606,"shares":19690476,"dividePrice":0,"high":0.9007,"amplitude":0.026756,"preClose":0.900728,"low":0.8766,"week52Low":0.6005,"pbRate":"1.47","psRate":"0.16","week52High":2.08,"institutionHeld":0,"latestPrice":0.89045,"eps":-0.073391,"divideRate":0,"volume":17979,"delay":0,"ttmEps":-0.073391,"open":0.9006,"prevYearClose":1.22,"prevWeekClose":0.896,"prevMonthClose":0.9019,"prevQuarterClose":1.03,"fiveDayClose":0.888,"twentyDayClose":0.94,"sixtyDayClose":1.13},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"MSS\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2544915669","title":"BRIEF-Maison Solutions announces closure Of Super HK of El Monte - SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2544915669","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2544915669?lang=en_us&edition=fundamental","pubTime":"2025-06-18 06:08","pubTimestamp":1750198115,"startTime":"0","endTime":"0","summary":"BRIEF-Maison Solutions announces closure Of Super HK of El Monte - SEC FilingJune 17  - Maison Solutions Inc MSS.O:MAISON SOLUTIONS INC - ANNOUNCES CLOSURE OF CLOSURE OF SUPER HK OF EL MONTE - SEC FILINGMAISON SOLUTIONS INC - CLOSURE COSTS EXPECTED TO BE IMMATERIAL - SEC FILINGSource text: [ID:n0001213900-25-055268]Further company coverage: MSS.O ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250617:nFWN3SK1QD:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MSS","BK4113"],"gpt_icon":0},{"id":"2544548915","title":"Maison Solutions Inc. Closes El Monte Supermarket","url":"https://stock-news.laohu8.com/highlight/detail?id=2544548915","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2544548915?lang=en_us&edition=fundamental","pubTime":"2025-06-18 05:50","pubTimestamp":1750197034,"startTime":"0","endTime":"0","summary":"Maison Solutions Inc. Class A ( ($MSS) ) has provided an announcement. On June 11, 2025, Maison Solutions Inc. announced the closure of its El Mont...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/maison-solutions-inc-closes-el-monte-supermarket?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/maison-solutions-inc-closes-el-monte-supermarket?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4113","MSS"],"gpt_icon":0},{"id":"2544913488","title":"Maison Solutions Inc - Announces Closure of Closure of Super HK of El Monte - SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2544913488","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2544913488?lang=en_us&edition=fundamental","pubTime":"2025-06-18 05:25","pubTimestamp":1750195508,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250617:nFWN3SK1QD:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4113","MSS"],"gpt_icon":0},{"id":"2543868470","title":"Press Release: Viasat Announces Comprehensive Agreement with Ligado Networks","url":"https://stock-news.laohu8.com/highlight/detail?id=2543868470","media":"Dow Jones","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2543868470?lang=en_us&edition=fundamental","pubTime":"2025-06-13 20:30","pubTimestamp":1749817800,"startTime":"0","endTime":"0","summary":"CARLSBAD, Calif., June 13, 2025  -- Viasat, Inc. , a global leader in satellite communications, today announced that its subsidiary Inmarsat Global Ltd.  has agreed to a binding term sheet with Ligado Networks  and AST & Science, LLC  to settle Inmarsat's opposition to Ligado's planned restructuring. Under the conditions set forth in the term sheet, Viasat anticipates receiving $568 million from Ligado in fiscal year 2026, which will primarily be used to manage near term maturities and address its extended maturity profile.Under the conditions of the term sheet, and subject to Bankruptcy Court approval, Inmarsat, Ligado and AST agreed to the following:. -- Starting on September 30, 2025, Ligado will resume making quarterly. payments of $16 million per quarter to Inmarsat. The quarterly payment. -- Ligado will make a $420 million lump sum payment to Inmarsat on October. 31, 2026. Including the December and March quarterly payments, Inmarsat. MSS services while ensuring the interference-","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4113","BK4020","VSAT","MSS"],"gpt_icon":0},{"id":"2542518911","title":"Think Palantir Stock Is Too Expensive? 1.28 Billion Reasons That Might Change Your Mind","url":"https://stock-news.laohu8.com/highlight/detail?id=2542518911","media":"Motley Fool","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2542518911?lang=en_us&edition=fundamental","pubTime":"2025-06-12 18:05","pubTimestamp":1749722700,"startTime":"0","endTime":"0","summary":"Palantir stock was just awarded a massive deal from the Department of Defense.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.fool.com/investing/2025/06/12/think-palantir-stock-is-too-expensive-128-billion/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"fool_stock","symbols":["PLTR","IE00B19Z9Z06.USD","LU1861558580.USD","IE00B894F039.SGD","IE00B29SXL02.USD","SWP","IE00BZ9MQY76.HKD","BK4585","IE00B19Z9P08.USD","DOD","BK4588","BK4547","BK4613","BK4023","BK4113","BK4543","MSS","LU1861559042.SGD","IE00B29SXK94.USD"],"gpt_icon":1},{"id":"2540053241","title":"Marjorie Taylor Greene Just Loaded Up on This Monster Artificial Intelligence (AI) Stock That Continues to Crush the Market","url":"https://stock-news.laohu8.com/highlight/detail?id=2540053241","media":"Motley Fool","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2540053241?lang=en_us&edition=fundamental","pubTime":"2025-06-04 17:06","pubTimestamp":1749027960,"startTime":"0","endTime":"0","summary":"Public records show that U.S. Rep. Marjorie Taylor Greene  recently bought shares in data analytics darling Palantir Technologies.Palantir stock has crushed the market this year, thanks in large part to major contract wins and its ability to outmaneuver new tariff policies.While following the momentum in Palantir stock can be tempting, the company's current valuation trends look unsustainable.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.fool.com/investing/2025/06/04/marjorie-taylor-greene-just-loaded-up-on-this-mons/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"fool_stock","symbols":["LU0203347892.USD","LU2237443622.USD","LU0823417653.USD","CSCO","BK4550","LU1046421795.USD","LU1235294995.USD","IE00BVYPNW00.USD","SG9999001424.SGD","LU1506573853.SGD","LU0731783394.SGD","LU1823568750.SGD","LU1883839398.USD","LU2237443978.SGD","BK4023","IE00B19Z9Z06.USD","LU1880398554.USD","BK4528","BK4525","BK4560","LU1066051498.USD","BK4020","LU2237443895.HKD","SG9999001440.SGD","IE00B29SXK94.USD","IE00BDGV0183.EUR","LU1066051811.HKD","IE00BFMHRM44.USD","DOD","LU2506951958.HKD","IE00B42XCP33.USD","LU1267930813.SGD","BK4527","LU2237443465.HKD","LU0348723411.USD","IE00B894F039.SGD","MSS","SG9999015945.SGD","BK4579","BK4587","SG9999015986.USD","BK4581","LU1244550494.USD","IE00BZ1G4Q59.USD","BK4588","LU0792757196.USD","PLTR","LU2237443382.USD","BK4113"],"gpt_icon":1},{"id":"2534101229","title":"Press Release: Agenus Reports Q1 2025 Financial Results and Key Business Updates","url":"https://stock-news.laohu8.com/highlight/detail?id=2534101229","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2534101229?lang=en_us&edition=fundamental","pubTime":"2025-05-12 19:30","pubTimestamp":1747049400,"startTime":"0","endTime":"0","summary":"-- BOT/BAL Achieves Breakthrough Response Rates in MSS Cancers -- Oral AACR. -- Seasoned Leader Onboard to Accelerate BOT/BAL Toward Registration. -- Near-Term Capital Transaction Poised to Bolster Liquidity. Agenus Inc.  , a leader in immuno-oncology, today reported financial and operational results for the first quarter of 2025, and shared key clinical and strategic milestones supporting the advancement of its botensilimab  and balstilimab  program.\"The growing strength of our BOT/BAL data across multiple hard-to-treat cancers reinforces our conviction in its transformative potential and fuels our unwavering commitment to delivering this combination to patients,\" said Garo Armen, Ph.D., Chairman and CEO of Agenus. \"With expanded datasets, key leadership appointments, and the FDA's renewed focus on accelerating cures and meaningful treatments, Agenus is entering a pivotal phase--advancing toward regulatory engagement with financial discipline and a sharp focus on bringing innovative i","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BK4113","BAL","MSS","AGEN"],"gpt_icon":0},{"id":"2533281662","title":"Bitcoin, Ethereum, XRP, Dogecoin Slide As Markets Brace For Fed Interest Rate Decision","url":"https://stock-news.laohu8.com/highlight/detail?id=2533281662","media":"Benzinga","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2533281662?lang=en_us&edition=fundamental","pubTime":"2025-05-07 03:52","pubTimestamp":1746561173,"startTime":"0","endTime":"0","summary":"Cryptocurrency markets continued trending lower early this week, with market participants eyeing Wednesday’s FOMC meeting and Federal Reserve Chair Jerome Powell&#39;s speech.","market":"nz","thumbnail":"https://www.benzinga.com/files/images/story/2025/05/06/Cryptocurrency-On-Binance-Trading-App--B_0.jpeg","type":0,"news_type":0,"thumbnails":["https://www.benzinga.com/files/images/story/2025/05/06/Cryptocurrency-On-Binance-Trading-App--B_0.jpeg"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/markets/cryptocurrency/25/05/45234515/bitcoin-ethereum-xrp-dogecoin-slide-as-markets-brace-for-fed-interest-rate-decision","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"Benzinga","symbols":["EZET","BTC.USD.HKCC","QETH","ETHV","FETH","BK4585","ETH.USD.CC","BK4588","BK4113","MSS","CETH","ETH.USD.HKCC","SOL.USD.HKCC","BTC.USD.CC","BK4594","BK4601","DOGE.USD.HKCC","LDO.USD.HKCC"],"gpt_icon":1},{"id":"2530267451","title":"Prediction: Palantir's New Deal With NATO Could Revolutionize How Artificial Intelligence (AI) Is Used in the Public Sector. Here's Why.","url":"https://stock-news.laohu8.com/highlight/detail?id=2530267451","media":"Motley Fool","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2530267451?lang=en_us&edition=fundamental","pubTime":"2025-04-28 00:00","pubTimestamp":1745769600,"startTime":"0","endTime":"0","summary":"NATO recently partnered with Palantir and will be deploying the company's Maven Smart System.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.fool.com/investing/2025/04/27/prediction-palantirs-new-deal-with-nato-could-revo/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"fool_stock","symbols":["PLTR","BK4547","LU1861559042.SGD","BK4588","IE00B29SXL02.USD","BK4613","BK4543","DOD","LU1861558580.USD","IE00B29SXK94.USD","BK4587","BK4585","BK4023","AI","BK4113","BK4528","MSS","NATO","BK4551"],"gpt_icon":1},{"id":"2529803206","title":"Adagene Announces Upcoming Poster Presentation on Masked Anti-CTLA-4 SAFEbody® ADG126 (Muzastotug) at American Society of Clinical Oncology (ASCO) Annual Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2529803206","media":"GlobeNewswire","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2529803206?lang=en_us&edition=fundamental","pubTime":"2025-04-23 22:05","pubTimestamp":1745417100,"startTime":"0","endTime":"0","summary":"SAN DIEGO and SUZHOU, China, April 23, 2025  -- Adagene Inc.  , a company transforming the discovery and development of novel antibody-based therapies, today announced a poster presentation at ASCO 2025 in Chicago, IL, May 30 - June 3.Abstract Title:Safety and Efficacy of ADG126  in Combination with Pembrolizumab: Updated Results of Phase 1b/2 Study in Advanced MSS CRC. Poster will be made available on the Publications page of the company’s websitehere.Powered by its proprietaryDynamic Precision Library platform, composed of NEObody, SAFEbody, and POWERbody technologies, Adagene’s highly differentiated pipeline features novel immunotherapy programs. The company’s SAFEbody technology is designed to address safety and tolerability challenges associated with many antibody therapeutics by using precision masking technology to shield the binding domain of the biologic therapy. Through activation in the tumor microenvironment, this allows for tumor-specific targeting of antibodies, while min","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/adagene-announces-upcoming-poster-presentation-140500747.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4139","BK4113","BK4117","CRC","LU0266512127.USD","MSS","BK4107","AFG","BK4213","LU0456854461.SGD","ADAG"],"gpt_icon":0},{"id":"2527492277","title":"Leap Therapeutics to Host Virtual KOL Event to Discuss Sirexatamab (DKN-01) in Second-line Patients with Advanced Microsatellite Stable Colorectal Cancer","url":"https://stock-news.laohu8.com/highlight/detail?id=2527492277","media":"PR Newswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2527492277?lang=en_us&edition=fundamental","pubTime":"2025-04-15 19:00","pubTimestamp":1744714800,"startTime":"0","endTime":"0","summary":"Virtual KOL Event on Wednesday, April 23, 2025, at 2:30 p.m. ET. CAMBRIDGE, Mass., April 15, 2025 /PRNewswire/ --Leap Therapeutics, Inc. , a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today announced it will host a virtual key opinion leader  event featuring Zev A. Wainberg, MD, Professor of Medicine at University of California, Los Angeles  and co-director of the UCLA GI Oncology Program, on Wednesday, April 23, 2025 at 2:30 p.m. ET. To register, please click here.Dr. Wainberg will connect with Leap's Chief Medical Officer, Cynthia Sirard, MD, to discuss the unmet need and how sirexatamab  may improve upon the current treatment landscape for previously treated patients with advanced microsatellite stable  colorectal cancer .The event will focus on reviewing the positive data from Part B of the Phase 2 DeFianCe study of sirexatamab in second-line patients with advanced MSS CRC. Sirexatamab, Leap's most advanced clinical program, is a humanize","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/leap-therapeutics-host-virtual-kol-110000836.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/leap-therapeutics-host-virtual-kol-110000836.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["CRC","HST","LPTX","LU0266512127.USD","BK4563","IE00B19Z4B17.USD","LENZ","KOL","IE0031619046.USD","IE00B7SZL793.SGD","BK4181","IE00B66KJ199.SGD","BK4588","AEIS","BK4213","LU0456854461.SGD","BK4157","BK4218","BK4113","BK4007","BK4139","MSS","BK4585","BK4505"],"gpt_icon":0},{"id":"2526647980","title":"BRIEF-Maison Solutions Files Prospectus For Proposed Resale From Time To Time By Selling Stockholder Of Up To 62.7 Million Shares Of Class A Common Stock","url":"https://stock-news.laohu8.com/highlight/detail?id=2526647980","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2526647980?lang=en_us&edition=fundamental","pubTime":"2025-04-12 05:55","pubTimestamp":1744408506,"startTime":"0","endTime":"0","summary":"BRIEF-Maison Solutions Files Prospectus For Proposed Resale From Time To Time By Selling Stockholder Of Up To 62.7 Million Shares Of Class A Common StockApril 11  - Maison Solutions Inc MSS.O:MAISON SOLUTIONS FILES PROSPECTUS FOR PROPOSED RESALE FROM TIME TO TIME BY SELLING STOCKHOLDER OF UP TO 62.7 MILLION SHARES OF CLASS A COMMON STOCKSource text: [ID:n0001213900-25-031176]Further company coverage: MSS.O ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250411:nFWN3QP1SJ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MSS","BK4113"],"gpt_icon":0},{"id":"2526671986","title":"Maison Solutions Inc. (NASDAQ:MSS) Might Not Be As Mispriced As It Looks After Plunging 25%","url":"https://stock-news.laohu8.com/highlight/detail?id=2526671986","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2526671986?lang=en_us&edition=fundamental","pubTime":"2025-04-11 18:52","pubTimestamp":1744368743,"startTime":"0","endTime":"0","summary":"Maison Solutions Inc. ( NASDAQ:MSS ) shares have had a horrible month, losing 25% after a relatively good period...","market":"us","thumbnail":"https://images.simplywall.st/asset/industry/5023000-choice2-main-header/1585186769297","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/5023000-choice2-main-header/1585186769297"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/consumer-retailing/nasdaq-mss/maison-solutions/news/maison-solutions-inc-nasdaqmss-might-not-be-as-mispriced-as-1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["MSS","QLD","USAW.SI","USJW.SI","IE00B64PRP62.GBP","MNQmain","IE00BGHQF748.EUR","LU2210150020.SGD","QID","NQmain","BK4585","TQQQ","BK4588","PSQ","TSYW.SI",".IXIC","IE00BKPKM429.USD","BK4113","LU2095319765.USD","BK4112","LU2210149790.SGD","NDAQ","NVIW.SI","SQQQ","IE00B3QW5Z07.USD"],"gpt_icon":1},{"id":"2525017693","title":"Adagene to Present at Stifel’s 2025 Virtual Targeted Oncology Forum","url":"https://stock-news.laohu8.com/highlight/detail?id=2525017693","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2525017693?lang=en_us&edition=fundamental","pubTime":"2025-04-07 20:00","pubTimestamp":1744027200,"startTime":"0","endTime":"0","summary":"SAN DIEGO and SUZHOU, China, April  07, 2025  (GLOBE NEWSWIRE) -- Adagene Inc. (“Adagene”) (Nasdaq: ADAG), a company transforming the discovery and development of novel antibody-based therapies, today","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/04/07/3056677/0/en/Adagene-to-Present-at-Stifel-s-2025-Virtual-Targeted-Oncology-Forum.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SF","LU0456854461.SGD","ADAG","MSS","LU0266512127.USD","BK4127","CRC","BK4179","BK4139","BK4113","BK4213","FET"],"gpt_icon":0},{"id":"2522558078","title":"Sensei Biotherapeutics Reports Favorable Preliminary Dose Expansion Data for Solnerstotug in PD-(L)1 Resistant Tumors","url":"https://stock-news.laohu8.com/highlight/detail?id=2522558078","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522558078?lang=en_us&edition=fundamental","pubTime":"2025-03-28 04:05","pubTimestamp":1743105900,"startTime":"0","endTime":"0","summary":"– Initial clinical activity in a PD-1 resistant population, with an ORR almost three times higher than historical PD-1 rechallenge response rates, with data still maturing –。– One durable complete response in a Merkel Cell Carcinoma  patient and two partial responses , including one in a second MCC patient and one in a microsatellite instability-high  Colorectal Cancer  patient, all of whom were previously treated with and progressed on immunotherapy –。– All PD-1 resistant “hot” tumor patients with tumor shrinkage remain on study, suggesting potential for deepening responses over time –。The Phase 1 dose expansion trial is a multi-center, open-label, dose expansion study evaluating solnerstotug as monotherapy and in combination withLibtayo , Regeneron’s PD-1 inhibitor, in both a basket of “hot” tumorsthat typically respond to immunotherapy but have progressed on prior PD-1 therapy and a single “cold” tumor histology  that is typically unresponsive to immunotherapy.At the time of this da","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/sensei-biotherapeutics-reports-favorable-preliminary-200500147.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["IE0031619046.USD","L","LU1169589451.USD","BK4139","SITC","BK4161","IE00B66KJ199.SGD","RCC","BK4080","BK4213","LU0266512127.USD","BK4585","CRS","LU0456854461.SGD","SD","PR","BK4588","LU0053666078.USD","LU2065731478.USD","BK4023","MSS","IE00B7SZL793.SGD","SNSE","BK4006","IE00B19Z4B17.USD","CR","CRC","LU1169590202.USD","BK4107","BK4113","PD","BK4231"],"gpt_icon":0},{"id":"2522455332","title":"Penny Stock Leap Therapeutics Unveils Positive Data From Experimental Combo Therapy For Colorectal Cancer","url":"https://stock-news.laohu8.com/highlight/detail?id=2522455332","media":"Benzinga","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522455332?lang=en_us&edition=fundamental","pubTime":"2025-03-27 01:29","pubTimestamp":1743010151,"startTime":"0","endTime":"0","summary":"Leap Therapeutics, Inc. presented updated preliminary data on Wednesday from Part B of the DeFianCe Phase 2 trial of sirexatamab  in combination with bevacizumab and chemotherapy  compared to bevacizumab and chemotherapy .The trial enrolled patients with advanced microsatellite stable  colorectal cancer  who have received one prior systemic therapy for advanced disease.The updated analysis shared on Wednesday includes the overall response rate , an additional two months of patient follow-up for progression-free survival , and initial overall survival  data.As ofMarch 12, 2025, 34 patients remain on the study drug in the sirexatamab Experimental Arm compared to 24 patients in the Control Arm.In patients with highDKK1levels, the sirexatamab Experimental Arm has a statistically significant 32% higher ORR, 3.5 months longer PFS, and OS compared to the Control Arm:. In patients who had not received prior anti-VEGF therapy, the sirexatamab Experimental Arm has a statistically significant 22%","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/penny-stock-leap-therapeutics-unveils-172911695.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["IE00BMPRXQ63.HKD","LENZ","BK4211","LU0266512127.USD","BK4563","LU0456854461.SGD","LPTX","BK4543","BK4585","BK4505","CRC","ONC","BK4213","BK4588","BK4097","ORR","OS","BK4141","MSS","BK4195","PFS","BK4113","BK4609","IE00BMPRXN33.USD","LU0348723411.USD","IE00BMPRXR70.SGD","BK4139"],"gpt_icon":1},{"id":"2522187556","title":"Leap Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2522187556","media":"PR Newswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522187556?lang=en_us&edition=fundamental","pubTime":"2025-03-26 19:05","pubTimestamp":1742987100,"startTime":"0","endTime":"0","summary":"Leap to host a conference call to present updated CRC clinical data today, March 26, 2025, at 8:00 a.m. ET. CAMBRIDGE, Mass., March 26, 2025 /PRNewswire/ -- Leap Therapeutics, Inc. , a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today reported financial results for the fourth quarter and year ended December 31, 2024.Reported positive updated data from Part B of the Phase 2 DeFianCe study of sirexatamab  in second-line patients with advanced microsatellite stable  colorectal cancer  confirming:. Statistically significant 22% higherORR and 2.6 month longer PFS in patients who had not had prior anti-VEGF therapy. FL-501 abstract accepted for poster presentation at the 2025 American Association for Cancer Research  Annual Meeting.Across the intent-to-treat population, thesirexatamab Experimental Arm had improved ORR compared to the Control Arm, with PFS and OS maturing with a higher number of patients continuing to","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/leap-therapeutics-reports-fourth-quarter-110500189.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/leap-therapeutics-reports-fourth-quarter-110500189.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4588","BK4113","BK4195","BK4211","MSS","BK4609","OS","IE00BMPRXN33.USD","PFS","BK4563","ORR","LU0266512127.USD","CRC","BK4543","BK4141","BK4097","LENZ","LU0348723411.USD","IE00BMPRXR70.SGD","BK4505","LU0456854461.SGD","BK4213","LPTX","BK4585","BK4139","IE00BMPRXQ63.HKD"],"gpt_icon":1},{"id":"2522596875","title":"Leap Therapeutics Reports Positive Updated Data from Sirexatamab Colorectal Cancer Study","url":"https://stock-news.laohu8.com/highlight/detail?id=2522596875","media":"PR Newswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522596875?lang=en_us&edition=fundamental","pubTime":"2025-03-26 19:00","pubTimestamp":1742986800,"startTime":"0","endTime":"0","summary":"Updated data confirms statistically significant 32% higher ORR and 3.5 month longer PFSin second-line CRC patients with high DKK1 levels treated with sirexatamab plus bevacizumab and chemotherapy. Statistically significant 22% higher ORR and 2.6 month longer PFSin patients who had not had prioranti-VEGF therapy. Leap to host a conference call to present clinical data today, March 26, 2025, at 8:00 a.m. ET. \"The updated data from Part B of the DeFianCe study presented today confirms that sirexatamab can generate significantly higher ORR and longer PFS in CRC patients who have high levels of DKK1 or who have not had prior anti-VEGF therapy, two exploratory populations with strong scientific rationale. In the full intent-to-treat population, sirexatamab demonstrated a higher ORR and a tail population with longer PFS that continues to mature. With more sirexatamab-treated patients currently continuing on study drug than control arm patients, there is potential for the dataset to continue t","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/leap-therapeutics-reports-positive-updated-110000183.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/leap-therapeutics-reports-positive-updated-110000183.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4097","PFS","BK4141","LU0348723411.USD","BK4139","LU0456854461.SGD","BK4543","LPTX","BK4505","BK4195","CRC","BK4585","LU0266512127.USD","BK4563","IE00BMPRXR70.SGD","IE00BMPRXQ63.HKD","MSS","BK4609","OS","BK4213","BK4211","BK4588","BK4113","ARM","ORR","LENZ","IE00BMPRXN33.USD"],"gpt_icon":0},{"id":"2521747504","title":"Adagene Reports Full Year 2024 Financial Results and Provides Corporate Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2521747504","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2521747504?lang=en_us&edition=fundamental","pubTime":"2025-03-24 20:00","pubTimestamp":1742817600,"startTime":"0","endTime":"0","summary":"Muzastotug Phase 2 dose expansion in MSS CRC with a 20 mg/kg loading dose regimen shows 33% overall response rate with four confirmed partial responses. SAFEbody technology utilized to create masked T cell engagers for potentially superior safety profile with enhanced therapeutic index. Cash balance of $85.2 million provides runway into late 2026. SAN DIEGO and SUZHOU, China, March 24, 2025  -- Adagene Inc.  , a platform-driven, clinical-stage biotechnology company transforming the discovery and development of novel anti-body-based therapies, today reported financial results for the full year 2024 and provided corporate updates.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/adagene-reports-full-2024-financial-120000486.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["ADAG","HCC","BK4113","MSS","BK4006","BK4139","BK4213","CRC","LU0456854461.SGD","LU0266512127.USD"],"gpt_icon":0},{"id":"2521478984","title":"Maison Solutions Names Xintong Ma as Chief Strategy Officer","url":"https://stock-news.laohu8.com/highlight/detail?id=2521478984","media":"MT Newswires Live","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2521478984?lang=en_us&edition=fundamental","pubTime":"2025-03-21 16:06","pubTimestamp":1742544373,"startTime":"0","endTime":"0","summary":"Maison Solutions (MSS) said late Thursday it appointed Xintong Ma as new chief strategy officer in a consulting role.Ma founded Zhekou Niu Information Technology in 2019.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4596","BK4516","BK4113","BK4600","BK4588","BK4595","BK4585","MSS","STRK","BK4023"],"gpt_icon":0}],"pageSize":20,"totalPage":3,"pageCount":1,"totalSize":43,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/MSS\",params:#limit:5,,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"MSS\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"MSS\",market:\"US\",delay:false,,,undefined,":{},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/MSS\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"MSS","date":"2025-06-18","current":-12.974303,"percent":0.366995,"low":-131.978833,"twenty":-77.484348,"median":-8.13082,"eighty":19.26571,"high":171.736597,"avg":-10.941169,"sd":61.606745,"marketCap":17140559},"quantilePoints":[{"date":"2023-10-06","current":95.051104,"twenty":42.433528,"median":42.433528,"eighty":52.957043,"marketCap":165760000},{"date":"2023-10-13","current":53.890581,"twenty":42.433528,"median":52.19324,"eighty":70.694259,"marketCap":93980000},{"date":"2023-10-20","current":85.821811,"twenty":42.433528,"median":55.481838,"eighty":70.694259,"marketCap":149665000},{"date":"2023-10-27","current":82.74538,"twenty":44.046002,"median":56.330509,"eighty":81.726975,"marketCap":144300000},{"date":"2023-11-03","current":84.12447,"twenty":51.089968,"median":63.915503,"eighty":85.482343,"marketCap":146705000},{"date":"2023-11-10","current":96.960613,"twenty":53.551113,"median":69.378819,"eighty":87.328201,"marketCap":169090000},{"date":"2023-11-17","current":98.817079,"twenty":54.208832,"median":80.199368,"eighty":94.520685,"marketCap":172327500},{"date":"2023-11-24","current":140.573349,"twenty":55.481838,"median":84.97314,"eighty":96.960613,"marketCap":245146426},{"date":"2023-12-01","current":163.945785,"twenty":56.330509,"median":86.140063,"eighty":104.492564,"marketCap":285905711},{"date":"2023-12-08","current":163.719965,"twenty":58.240018,"median":88.420865,"eighty":140.573349,"marketCap":285511902},{"date":"2023-12-15","current":171.736597,"twenty":59.40694,"median":91.656421,"eighty":155.816242,"marketCap":299492139},{"date":"2023-12-22","current":25.627315,"twenty":53.890581,"median":88.420865,"eighty":152.316023,"marketCap":33473809},{"date":"2023-12-29","current":20.803349,"twenty":47.270951,"median":87.625236,"eighty":147.980266,"marketCap":27172856},{"date":"2024-01-05","current":17.336124,"twenty":42.433528,"median":86.087021,"eighty":144.841359,"marketCap":22644047},{"date":"2024-01-12","current":13.568909,"twenty":34.099403,"median":84.12447,"eighty":143.192868,"marketCap":17723397},{"date":"2024-01-19","current":11.411692,"twenty":24.572072,"median":77.653357,"eighty":140.573349,"marketCap":14905690},{"date":"2024-01-26","current":12.831747,"twenty":17.788371,"median":69.166652,"eighty":140.573349,"marketCap":16760533},{"date":"2024-02-02","current":13.733225,"twenty":15.074891,"median":59.40694,"eighty":106.508156,"marketCap":17938023},{"date":"2024-02-09","current":16.58238,"twenty":14.125173,"median":55.906174,"eighty":105.447318,"marketCap":21659523},{"date":"2024-02-16","current":25.175067,"twenty":14.548777,"median":53.466246,"eighty":104.492564,"marketCap":32883094},{"date":"2024-02-23","current":21.104847,"twenty":14.726058,"median":42.433528,"eighty":104.32283,"marketCap":27566666},{"date":"2024-03-01","current":23.064583,"twenty":15.013988,"median":42.433528,"eighty":102.667922,"marketCap":30126428},{"date":"2024-03-08","current":23.818328,"twenty":15.316089,"median":36.028989,"eighty":99.506624,"marketCap":31110952},{"date":"2024-03-15","current":19.29586,"twenty":16.341182,"median":28.039296,"eighty":97.331906,"marketCap":25203809},{"date":"2024-03-22","current":-113.246356,"twenty":14.726058,"median":26.833306,"eighty":95.433006,"marketCap":26188333},{"date":"2024-03-28","current":-118.355211,"twenty":13.992212,"median":25.627315,"eighty":93.459846,"marketCap":27369761},{"date":"2024-04-05","current":-107.286018,"twenty":13.539061,"median":24.948944,"eighty":91.953456,"marketCap":24809999},{"date":"2024-04-12","current":-102.177162,"twenty":13.066915,"median":24.270574,"eighty":90.128814,"marketCap":23628571},{"date":"2024-04-19","current":-103.880113,"twenty":11.529276,"median":23.969076,"eighty":89.04676,"marketCap":24022380},{"date":"2024-04-26","current":-93.662397,"twenty":-30.862157,"median":23.667579,"eighty":88.304173,"marketCap":21659523},{"date":"2024-05-03","current":-88.553541,"twenty":-92.12974,"median":23.064583,"eighty":87.710103,"marketCap":20478095},{"date":"2024-05-10","current":-102.177162,"twenty":-99.62273,"median":22.913834,"eighty":86.734132,"marketCap":23628571},{"date":"2024-05-17","current":-103.028636,"twenty":-100.474208,"median":21.858591,"eighty":86.076413,"marketCap":23825475},{"date":"2024-05-24","current":-91.959447,"twenty":-100.474208,"median":20.803349,"eighty":85.906678,"marketCap":21265714},{"date":"2024-05-31","current":-92.81092,"twenty":-100.474208,"median":19.29586,"eighty":85.142875,"marketCap":21462618},{"date":"2024-06-07","current":-97.068302,"twenty":-100.474208,"median":18.391367,"eighty":83.572834,"marketCap":22447142},{"date":"2024-06-14","current":-120.909639,"twenty":-100.474208,"median":17.562248,"eighty":81.726975,"marketCap":27960475},{"date":"2024-06-21","current":-108.137496,"twenty":-102.177162,"median":16.808503,"eighty":77.653357,"marketCap":25006904},{"date":"2024-06-28","current":-123.464072,"twenty":-102.177162,"median":15.979384,"eighty":77.483623,"marketCap":28551190},{"date":"2024-07-05","current":-112.394878,"twenty":-102.177162,"median":14.922634,"eighty":75.658981,"marketCap":25991428},{"date":"2024-07-12","current":-108.988973,"twenty":-103.709818,"median":14.125173,"eighty":69.293952,"marketCap":25203809},{"date":"2024-07-15","current":-110.691923,"twenty":-104.385891,"median":14.100299,"eighty":69.209085,"marketCap":25597618},{"date":"2024-08-02","current":-90.256492,"twenty":-104.217298,"median":14.075425,"eighty":69.124218,"marketCap":20871904},{"date":"2024-08-09","current":-77.484348,"twenty":-103.369227,"median":13.651067,"eighty":68.636233,"marketCap":17918333},{"date":"2024-08-16","current":-5.24654,"twenty":-103.028636,"median":13.49655,"eighty":63.01379,"marketCap":17524523},{"date":"2024-08-23","current":-3.995564,"twenty":-102.773194,"median":13.146812,"eighty":58.706787,"marketCap":13346007},{"date":"2024-08-30","current":-4.22317,"twenty":-102.347457,"median":12.831747,"eighty":57.094313,"marketCap":14106257},{"date":"2024-09-06","current":-4.83448,"twenty":-102.177162,"median":11.607666,"eighty":55.991041,"marketCap":16148159},{"date":"2024-09-13","current":-4.347554,"twenty":-102.177162,"median":11.115471,"eighty":54.845335,"marketCap":14521726},{"date":"2024-09-20","current":-4.715991,"twenty":-102.177162,"median":-3.808162,"eighty":53.720847,"marketCap":15752380},{"date":"2024-09-27","current":-10.100234,"twenty":-102.177162,"median":-3.90838,"eighty":52.278107,"marketCap":25597618},{"date":"2024-10-04","current":-9.478681,"twenty":-102.177162,"median":-3.985012,"eighty":47.270951,"marketCap":24022380},{"date":"2024-10-11","current":-9.711763,"twenty":-101.836571,"median":-4.110575,"eighty":42.433528,"marketCap":24613095},{"date":"2024-10-18","current":-8.235575,"twenty":-101.325685,"median":-4.244392,"eighty":42.433528,"marketCap":20871904},{"date":"2024-10-25","current":-7.847105,"twenty":-100.985094,"median":-4.358165,"eighty":42.433528,"marketCap":19887380},{"date":"2024-10-31","current":-7.110564,"twenty":-100.474208,"median":-4.421241,"eighty":41.484268,"marketCap":18020723},{"date":"2024-11-08","current":-8.157881,"twenty":-100.474208,"median":-4.598091,"eighty":37.35558,"marketCap":20674999},{"date":"2024-11-15","current":-7.614022,"twenty":-100.474208,"median":-4.763445,"eighty":35.546593,"marketCap":19296666},{"date":"2024-11-22","current":-7.610915,"twenty":-100.474208,"median":-4.848628,"eighty":32.682364,"marketCap":19288790},{"date":"2024-11-29","current":-7.304023,"twenty":-100.474208,"median":-5.421621,"eighty":28.94379,"marketCap":18511016},{"date":"2024-12-06","current":-6.992469,"twenty":-99.62273,"median":-5.705759,"eighty":27.134803,"marketCap":17721428},{"date":"2024-12-13","current":-8.080187,"twenty":-99.62273,"median":-6.992469,"eighty":27.134803,"marketCap":20478095},{"date":"2024-12-20","current":-7.310906,"twenty":-99.62273,"median":-7.07094,"eighty":26.833306,"marketCap":21068809},{"date":"2024-12-27","current":-7.925842,"twenty":-98.26037,"median":-7.186705,"eighty":25.868513,"marketCap":22840952},{"date":"2025-01-03","current":-8.472451,"twenty":-97.408893,"median":-7.304023,"eighty":25.627315,"marketCap":24416190},{"date":"2025-01-10","current":-8.814083,"twenty":-97.068302,"median":-7.345923,"eighty":25.446416,"marketCap":25400714},{"date":"2025-01-17","current":-7.242579,"twenty":-97.068302,"median":-7.379232,"eighty":25.114768,"marketCap":20871904},{"date":"2025-01-24","current":-7.720863,"twenty":-96.727712,"median":-7.38094,"eighty":24.994169,"marketCap":22250237},{"date":"2025-01-31","current":-7.648437,"twenty":-95.195057,"median":-7.420176,"eighty":24.81327,"marketCap":22041518},{"date":"2025-02-07","current":-7.857515,"twenty":-94.513875,"median":-7.443095,"eighty":24.511772,"marketCap":22644047},{"date":"2025-02-14","current":-8.609104,"twenty":-94.343579,"median":-7.452707,"eighty":24.240424,"marketCap":24809999},{"date":"2025-02-21","current":-8.745756,"twenty":-93.662397,"median":-7.458634,"eighty":24.119825,"marketCap":25203809},{"date":"2025-02-28","current":-8.13082,"twenty":-93.662397,"median":-7.515884,"eighty":24.119825,"marketCap":23431666},{"date":"2025-03-07","current":-9.292366,"twenty":-92.81092,"median":-7.526106,"eighty":23.818328,"marketCap":26779047},{"date":"2025-03-14","current":-9.22404,"twenty":-92.81092,"median":-7.54099,"eighty":23.818328,"marketCap":26582142},{"date":"2025-03-21","current":-15.798691,"twenty":-91.959447,"median":-7.58421,"eighty":23.667579,"marketCap":20871904},{"date":"2025-03-28","current":-16.842001,"twenty":-91.959447,"median":-7.614022,"eighty":23.51683,"marketCap":22250237},{"date":"2025-04-04","current":-15.351559,"twenty":-91.107969,"median":-7.646769,"eighty":23.064583,"marketCap":20281190},{"date":"2025-04-11","current":-15.351559,"twenty":-91.107969,"median":-7.652869,"eighty":23.064583,"marketCap":20281190},{"date":"2025-04-17","current":-15.05347,"twenty":-90.433599,"median":-7.691717,"eighty":23.064583,"marketCap":19887380},{"date":"2025-04-25","current":-14.475179,"twenty":-90.258195,"median":-7.745137,"eighty":22.943984,"marketCap":19123390},{"date":"2025-05-02","current":-14.680859,"twenty":-89.57531,"median":-7.847105,"eighty":22.431437,"marketCap":19395118},{"date":"2025-05-09","current":-13.042863,"twenty":-88.723836,"median":-7.847105,"eighty":22.190239,"marketCap":17231135},{"date":"2025-05-16","current":-14.345495,"twenty":-88.553541,"median":-7.857515,"eighty":21.677693,"marketCap":18952063},{"date":"2025-05-23","current":-15.05347,"twenty":-85.828817,"median":-7.924799,"eighty":21.195296,"marketCap":19887380},{"date":"2025-05-30","current":-13.123347,"twenty":-83.104091,"median":-7.925842,"eighty":20.923948,"marketCap":17337464},{"date":"2025-06-06","current":-13.266429,"twenty":-80.873221,"median":-8.062494,"eighty":20.803349,"marketCap":17526492},{"date":"2025-06-13","current":-13.23513,"twenty":-78.608296,"median":-8.105504,"eighty":19.898856,"marketCap":17485142},{"date":"2025-06-18","current":-12.974303,"twenty":-77.484348,"median":-8.13082,"eighty":19.26571,"marketCap":17140559}],"updateTime":1750492903794}}}